HER-2/neu Status in Breast Cancer Metastases to the Central Nervous System

Archives of Pathology and Laboratory Medicine

Volumn 127, Issue 11, 2003, Pages 1451-1457

  Lear Kaul, Kelly C ^a   Yoon, Hye Ryoung ^b,c   Kleinschmidt DeMasters, Bette K ^a   McGavran, Loris ^a   Singh, Meenakshi ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b Seoul Medical Science Institute   (South Korea)

^c Doo San Engineering Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ACCURACY; ADULT; ARTICLE; BRAIN BIOPSY; BRAIN METASTASIS; BREAST CANCER; CLINICAL ARTICLE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; PROTEIN EXPRESSION; BIOSYNTHESIS; BREAST TUMOR; CENTRAL NERVOUS SYSTEM TUMOR; CHROMOSOME 17; DNA PROBE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LUNG CARCINOMA; METASTASIS; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PROTO ONCOGENE; RETROSPECTIVE STUDY;

ADULT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 17; DNA PROBES; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES;

EID: 0242335682     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
2. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
3. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, target for therapy. Stem Cells. 1998;16:413-428.
4. Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol. 1999;112:S53-S67.
5. Nichols DW, Wolff DJ, Self S, et al. A testing algorithm for determination of HER2 status in patients with breast cancer. Ann Clin Lab Sci. 2002;32:3-11.
6. Niehans GA, Singleton TP, Dykoski D, Kiang DT. Stability of HER-2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst. 1993;85:1230-1235.
7. Masood S, Bui MM. Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. Ann Clin Lab Sci. 2000;30:259-265.
8. Tanner M, Jarvinen P, Isola J. Amplification of HER-2/neu and topoisomerase IIα in primary and metastatic breast cancer. Cancer Res. 2001;61:5345-5348.
9. Gancberg D, Di Leo A, Cardoso F, et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol. 2002;13:1036-1043.
10. Xu R, Perle M, Inghirami G, Chan W, Delgado Y, Feiner H. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Mod Pathol. 2002;15:116-124.
11. Tsukada Y, Fouad A, Pickren JW, Lane WW. Central nervous system metastasis from breast carcinoma. Cancer. 1983;52:2349-2354.
12. Leyland-Jones B. Trastuzumab therapy for the metastatic patient: does the primary match? Ann Oncol. 2002;13:993-994.
13. Harris LN, Liotcheva V, Broadwater G, et al. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol. 2001;19:1698-1706.
14. Wang S, Saboorian MH, Frenkel EP, et al. Assessment of HER-2/neu status in breast cancer: Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am J Clin Pathol. 2001;116:495-503.
15. Cianciulli AM, Botti C, Coletta AM, et al. Contribution of fluorescence in situ hybridization to immunohistochemistry for the evaluation of HER-2 in breast cancer. Cancer Genet Cytogenet. 2002;133:66-71.
16. Iglehart JD, Kraus MH, Langton BC, Huper G, Kerns BJ, Marks JR. Increased erbB-2 gene copies and expression in multiple stages of breast cancer. Cancer Res. 1990;50:6701-6707.
17. Teixeira MR, Pandis N, Bardi G, et al. Karyotypic comparisons of multiple tumours and macroscopically normal surrounding tissue samples from patients with breast cancer. Cancer Res. 1996;56:855-859.
18. Kuukajarvi T, Karhu R, Tanner M, et al. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res. 1997;57:1597-1604.